Colorado is currently home to 1774 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Neuroblastoma Maintenance Therapy Trial
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Rocky Mountain Pediatric Hematology, Denver, Colorado
Conditions: Neuroblastoma
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Ovarian Carcinoma
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Recruiting
The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.)
Gender:
ALL
Ages:
All
Trial Updated:
09/17/2024
Locations: Penrose Cancer Center, Colorado Springs, Colorado
Conditions: Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/16/2024
Locations: Colorado Medical Research Center, Denver, Colorado
Conditions: Non-segmental Vitiligo
Next Generation Rocklatan
Recruiting
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Eye Center of Northern Colorado, PC, Fort Collins, Colorado
Conditions: Open Angle Glaucoma, Ocular Hypertension
VIA Disc NP Registry 3.0
Recruiting
Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: MD Pain, Englewood, Colorado
Conditions: Discogenic Pain, Back Pain, Back Pain, Low
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Recruiting
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negativ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: University of Colorado, Denver, Colorado
Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Improving Care for Rural Patients With Solid Tumors
Recruiting
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cervical, breast, bladder, colon, and rectal cancers) in rural patients.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/13/2024
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Recruiting
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Multiple Myeloma
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer